Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise

Table 3 Base-case results for dapagliflozin compared to metformin

Outcomes	Metformin	Dapagliflozin	Difference^a
Events
MI	10.90%	11.01%	0.11%
Stroke	24.57%	25.40%	0.83%
CHF	15.56%	15.60%	0.03%
ESRD	4.748%	4.846%	0.097%
Blindness	5.17%	5.15%	− 0.02%
Clinical neuropathy	15.96%	16.00%	0.04%
Minor amputation	13.959%	13.963%	0.004%
Major amputation	10.501%	10.504%	0.003%
Total QALY	11.12	11.03	− 0.10
Total LY	24.86	24.71	− 0.15
Total cost (US $)	15,262	17,450	2188
ICER (US $/QALY)	NA	Dominated

MI myocardial infarction, CHF congestive heart failure, CVD cardiovascular disease, ESRD end-stage renal disease, DFU diabetic foot ulcer, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio
^aCompared with the control strategy (Metformin)

ISSN: 1478-7547